Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
Express Scripts, one of the country’s largest pharmacy benefit managers, sued the Federal Trade Commission (FTC) Tuesday and ...
Express Scripts parent company Cigna alleges the Federal Trade Commission ignored more than 3 million pages of documents the ...
The case accuses UnitedHealth Group Inc's Optum unit, CVS Health Corp's CVS Caremark and Cigna Corp's Express Scripts of unfairly excluding lower cost insulin products from lists of drugs ...
The timing is anything but a coincidence. The three largest PBMs – Express Scripts, CVS Caremark, and OptumRx – control approximately 80% of the prescription drug market. With such power ...
The FTC report said the companies responsible for controlling spending on drugs were sometimes steering patients toward more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback